Article

Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low An OncLive® Scientific Interchange and Workshop

This article provides a summary of data on treatment approaches for HER2-positive breast cancer presented at conferences in 2021 and offers a review of how findings may affect clinical approaches to escalating or de-escalating therapy in patients with early-stage disease, optimally sequencing HER2-targeted therapy in patients with metastatic breast cancer, and selecting HER2-targeted agents based on the burden of CNS disease.

Related Videos
Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
Linda Vahdat, MD, MBA
Peter Forsyth, MD
Bruce G. Haffty, MD, MS, FACR, FASTRO
Related Content
The OncFive: Top Oncology Articles for the Week of 8/25
August 31st 2024

The OncFive: Top Oncology Articles for the Week of 8/25

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
August 29th 2024

State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Shipra Gandhi, MD
August 26th 2024

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

Bruce G. Haffty, MD, MS
August 25th 2024

NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer